<!DOCTYPE html>
<html lang="zh-CN">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=5.0">
    <title>ç§‘ç ”æ—¥æŠ¥ - 2025-11-25</title>
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        body {
            font-family: -apple-system, BlinkMacSystemFont, "Segoe UI", Roboto, "Helvetica Neue", Arial, "Noto Sans", sans-serif, "Apple Color Emoji", "Segoe UI Emoji";
            line-height: 1.8;
            color: #2c3e50;
            background: linear-gradient(135deg, #f5f7fa 0%, #c3cfe2 100%);
            padding: 15px;
            font-size: 16px;
        }

        .container {
            max-width: 900px;
            margin: 0 auto;
            background: white;
            padding: 35px;
            border-radius: 16px;
            box-shadow: 0 10px 40px rgba(0,0,0,0.1);
        }

        /* æ ‡é¢˜ä¼˜åŒ– */
        h1 {
            color: #1a202c;
            font-size: 2em;
            border-bottom: 4px solid #667eea;
            padding-bottom: 15px;
            margin-bottom: 25px;
            font-weight: 700;
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            -webkit-background-clip: text;
            -webkit-text-fill-color: transparent;
            background-clip: text;
        }

        h2 {
            color: #2d3748;
            font-size: 1.5em;
            margin-top: 40px;
            margin-bottom: 20px;
            padding-left: 15px;
            border-left: 5px solid #667eea;
            font-weight: 600;
        }

        h3 {
            color: #4a5568;
            font-size: 1.25em;
            margin-top: 28px;
            margin-bottom: 14px;
            font-weight: 600;
        }

        /* åˆ†ç±»æµè§ˆæŠ˜å åŠŸèƒ½ */
        details {
            margin: 20px 0;
            border-radius: 8px;
            overflow: hidden;
        }

        details summary {
            cursor: pointer;
            padding: 15px 20px;
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            color: #2d3748;
            font-size: 1.25em;
            font-weight: 600;
            text-align: right;
            direction: rtl;
            border-right: 5px solid #667eea;
            transition: all 0.3s ease;
            list-style: none;
            user-select: none;
        }

        details summary * {
            direction: ltr;
        }

        details summary::-webkit-details-marker {
            display: none;
        }

        details summary::before {
            content: 'â–¶';
            display: inline-block;
            margin-left: 10px;
            transition: transform 0.3s ease;
            font-size: 0.8em;
        }

        details[open] summary::before {
            transform: rotate(90deg);
        }

        details summary:hover {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            box-shadow: 0 4px 12px rgba(102, 126, 234, 0.3);
        }

        details[open] summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            border-right-color: white;
        }

        details .details-content {
            padding: 20px;
            background: white;
            border: 1px solid #e9ecef;
            border-top: none;
        }

        h4 {
            color: #718096;
            font-size: 1.1em;
            margin-top: 22px;
            margin-bottom: 12px;
            font-weight: 600;
        }

        p {
            margin-bottom: 16px;
            line-height: 1.8;
        }

        blockquote {
            background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%);
            border-left: 4px solid #667eea;
            padding: 18px 22px;
            margin: 22px 0;
            border-radius: 8px;
            color: #4a5568;
            font-size: 0.95em;
            box-shadow: 0 2px 8px rgba(0,0,0,0.05);
        }

        blockquote p {
            margin-bottom: 8px;
        }

        blockquote p:last-child {
            margin-bottom: 0;
        }

        blockquote em {
            font-style: normal;
            color: #718096;
            font-size: 0.9em;
        }

        blockquote a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        blockquote a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* é¡¶éƒ¨ç½²åï¼ˆå±…å³ï¼‰ */
        .powered-by-top {
            text-align: right;
            font-size: 0.85em;
            color: #718096;
            font-style: italic;
            margin: 12px 0;
            padding-right: 5px;
        }

        .powered-by-top a {
            color: #667eea;
            font-weight: 500;
            border-bottom: 1px solid rgba(102, 126, 234, 0.3);
        }

        .powered-by-top a:hover {
            color: #764ba2;
            border-bottom-color: #764ba2;
        }

        /* AI æ€»ç»“åŒºåŸŸä¼˜åŒ– */
        .ai-summary {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            padding: 28px;
            border-radius: 16px;
            margin: 30px 0;
            box-shadow: 0 12px 35px rgba(102, 126, 234, 0.35);
            position: relative;
            overflow: hidden;
        }

        .ai-summary::before {
            content: '';
            position: absolute;
            top: -50%;
            right: -50%;
            width: 200%;
            height: 200%;
            background: radial-gradient(circle, rgba(255,255,255,0.1) 0%, transparent 70%);
            pointer-events: none;
        }

        .ai-summary h2 {
            color: white;
            border-left: none;
            border-right: none;
            margin-top: 0;
            margin-bottom: 18px;
            padding-left: 15px;
            padding-right: 0;
            text-align: left;
            direction: ltr;
        }

        .ai-summary h3 {
            color: #f0f0f0;
            margin-top: 18px;
            border-right: 3px solid rgba(255,255,255,0.5);
            padding-right: 12px;
            padding-left: 0;
            text-align: right;
            direction: rtl;
        }

        .ai-summary h3 * {
            direction: ltr;
        }

        .ai-summary blockquote {
            background: rgba(255,255,255,0.15);
            border-left-color: white;
            color: white;
            backdrop-filter: blur(10px);
        }

        .ai-summary p {
            color: white;
        }

        .ai-summary strong {
            color: #fff;
            font-weight: 600;
        }

        ul, ol {
            margin-left: 28px;
            margin-bottom: 18px;
        }

        li {
            margin-bottom: 12px;
            line-height: 1.8;
        }

        /* é“¾æ¥ä¼˜åŒ– */
        a {
            color: #667eea;
            text-decoration: none;
            border-bottom: 1px solid transparent;
            transition: all 0.3s ease;
            font-weight: 500;
        }

        a:hover {
            border-bottom-color: #667eea;
            color: #764ba2;
        }

        /* è¡¨æ ¼ä¼˜åŒ– */
        table {
            width: 100%;
            border-collapse: collapse;
            margin: 20px 0;
            box-shadow: 0 2px 12px rgba(0,0,0,0.08);
            border-radius: 10px;
            overflow: hidden;
        }

        th, td {
            border: 1px solid #e2e8f0;
            padding: 14px 18px;
            text-align: left;
        }

        th {
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            color: white;
            font-weight: 600;
            font-size: 0.95em;
        }

        tr:nth-child(even) {
            background: #f8f9fa;
        }

        tr:hover {
            background: #e9ecef;
            transition: background 0.3s ease;
        }

        /* å…³é”®è¯ç»Ÿè®¡è¡¨æ ¼ç‰¹æ®Šæ ·å¼ï¼ˆæ›´ç´§å‡‘ï¼‰ */
        .keywords-table {
            font-size: 0.9em;
            max-width: 600px;
        }

        .keywords-table th,
        .keywords-table td {
            padding: 10px 14px;
        }

        .keywords-table th {
            font-size: 0.9em;
        }

        hr {
            border: none;
            border-top: 2px solid #e2e8f0;
            margin: 40px 0;
        }

        strong {
            color: #2d3748;
            font-weight: 600;
        }

        code {
            background: #f1f5f9;
            padding: 3px 8px;
            border-radius: 5px;
            font-family: "SF Mono", Monaco, Consolas, "Courier New", monospace;
            font-size: 0.9em;
            color: #e53e3e;
        }

        /* ç¾åŒ–æ»šåŠ¨æ¡ */
        ::-webkit-scrollbar {
            width: 8px;
            height: 8px;
        }

        ::-webkit-scrollbar-track {
            background: #f1f1f1;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb {
            background: #667eea;
            border-radius: 4px;
        }

        ::-webkit-scrollbar-thumb:hover {
            background: #764ba2;
        }

        /* ç§»åŠ¨ç«¯ä¼˜åŒ– */
        @media (max-width: 768px) {
            body {
                padding: 8px;
                font-size: 15px;
            }

            .container {
                padding: 22px 18px;
                border-radius: 12px;
            }

            h1 {
                font-size: 1.6em;
                padding-bottom: 12px;
                margin-bottom: 20px;
            }

            h2 {
                font-size: 1.3em;
                margin-top: 30px;
                padding-left: 12px;
            }

            h3 {
                font-size: 1.15em;
            }

            h4 {
                font-size: 1.05em;
            }

            blockquote {
                padding: 14px 16px;
                margin: 18px 0;
            }

            .ai-summary {
                padding: 20px;
                margin: 22px 0;
            }

            .ai-summary-header {
                flex-direction: column;
                align-items: flex-start;
            }

            .powered-by {
                margin-left: 0;
                margin-top: 8px;
            }

            table {
                font-size: 0.85em;
            }

            th, td {
                padding: 10px 12px;
            }

            .keywords-table {
                font-size: 0.8em;
            }

            .keywords-table th,
            .keywords-table td {
                padding: 8px 10px;
            }

            ul, ol {
                margin-left: 22px;
            }
        }

        /* è¶…å°å±å¹• */
        @media (max-width: 480px) {
            body {
                font-size: 14px;
                padding: 5px;
            }

            .container {
                padding: 18px 14px;
            }

            h1 {
                font-size: 1.4em;
            }

            h2 {
                font-size: 1.2em;
            }

            .ai-summary {
                padding: 16px;
            }

            .powered-by {
                font-size: 0.7em;
            }
        }

        /* å¹³æ»‘æ»šåŠ¨ */
        html {
            scroll-behavior: smooth;
        }

        /* æé«˜å¯ç‚¹å‡»åŒºåŸŸ */
        @media (pointer: coarse) {
            a {
                padding: 4px 0;
                display: inline-block;
            }
        }

        /* æ‰“å°ä¼˜åŒ– */
        @media print {
            body {
                background: white;
                padding: 0;
            }

            .container {
                box-shadow: none;
                max-width: 100%;
            }

            .ai-summary {
                background: #f5f5f5;
                color: black;
                box-shadow: none;
            }

            .ai-summary h2,
            .ai-summary h3,
            .ai-summary p,
            .ai-summary strong {
                color: black;
            }
        }
    </style>
</head>
<body>
    <div class="container">
        <h1>ğŸ“… Daily Report - 2025-11-25</h1>
<blockquote>
<p>ä»Šæ—¥ç­›é€‰å‡º <strong>83</strong> æ¡å†…å®¹ï¼Œæ¥è‡ª <strong>5</strong> ä¸ªæ¥æº</p>
</blockquote>
<div class="powered-by-top">Powered by <a href="https://kyplus.de" target="_blank" rel="noopener noreferrer">ç§‘ç ”æ™®æ‹‰æ–¯</a> & <a href="https://claude.ai" target="_blank" rel="noopener noreferrer">Claude</a></div>

<hr />
<div class="ai-summary">
                <h2>ğŸ¤– ä»Šæ—¥AIæ™ºèƒ½æ€»ç»“</h2>
                <h3>ğŸ“° å…¬ä¼—å·</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
- é¦–æ¬¡æ­ç¤ºç™½è¡€ç—…å…ç–«é€ƒé€¸æœºåˆ¶ï¼Œå¹¶å¼€å‘å‡ºæ¢å¤Tç»†èƒæ”»å‡»èƒ½åŠ›çš„æŠ—ä½“ç–—æ³•ã€‚<br />
- å‘ç°å¹²æ‰°ç´ ä¿¡å·è¯±å¯¼çš„è¡°è€CD8+ Tç»†èƒæ˜¯å¯¼è‡´ä¸‰é˜´æ€§ä¹³è…ºç™Œæ²»ç–—è€è¯çš„å…³é”®å› ç´ ï¼Œå¹¶æå‡ºNMNè¡¥å……å¯é€†è½¬æ­¤è¿‡ç¨‹ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- è‚¿ç˜¤å…ç–«é€ƒé€¸æœºåˆ¶åŠå¹²é¢„ç­–ç•¥ï¼ŒåŒ…æ‹¬ç™½è¡€ç—…ã€ä¹³è…ºç™Œç­‰ã€‚<br />
- ç™Œç»†èƒä¼‘çœ ä¸ç»†èŒå…³è”æœºåˆ¶ã€‚<br />
- ç‚ç—‡æ€§è‚ ç—…æ²»ç–—ï¼Œé¶å‘è‚ é“ç›Šç”ŸèŒã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- ç©ºé—´å¤šç»„å­¦ï¼ˆè½¬å½•ç»„ã€ä»£è°¢ç»„ï¼‰ä¸å•ç»†èƒæŠ€æœ¯æ•´åˆåˆ†æã€‚<br />
- roplsåŒ…å®ç°é«˜æ•ˆå¤šå˜é‡ä»£è°¢ç»„å­¦æ•°æ®å¯è§†åŒ–ã€‚<br />
- CellWhispererã€CellMentorç­‰AIé©±åŠ¨çš„ç»†èƒæ¢ç´¢ä¸åˆ†ææ–°å·¥å…·ã€‚</p>
<h3>ğŸ§¬ æ•°æ®å‰æ²¿</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
*   <strong>é¦–æ¬¡</strong>æ­ç¤ºå°RNAåŸºå› ç»„å­¦åœ¨<strong>åŸƒåŠä¼ŠèšŠ</strong>ä¸­å‘ç°<strong>è¯±å¯¼RNAå¹²æ‰°ååº”çš„ç—…æ¯’</strong>ï¼ˆGSE309876, GSE309873ï¼‰ã€‚<br />
*   <strong>é¦–æ¬¡</strong>ç»˜åˆ¶<strong>å°é¼ ä¸‹é¢Œè½¯éª¨</strong>çš„<strong>å•ç»†èƒå›¾è°±</strong>ï¼Œæ­ç¤º<strong>éª¨éª¼ç¥–ç»†èƒå±‚çº§å’ŒåŒºåŸŸæ¨¡å¼</strong>ï¼ˆGSE305595ï¼‰ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
*   <strong>è‚¿ç˜¤å…ç–«ä¸è€è¯æ€§</strong>ï¼šæ¢ç´¢MEK/ERKé€šè·¯æŠ‘åˆ¶P-gpé€†è½¬å¤šå‘æ€§éª¨é«“ç˜¤å¡éä½ç±³è€è¯æ€§ï¼ˆGSE310880ï¼‰ï¼›åˆ†æ<strong>æ›¿ä»£æ€§RNAå‰ªæ¥</strong>ä¸<strong>å…ç–«æ£€æŸ¥ç‚¹æ²»ç–—ååº”</strong>çš„å…³è”ï¼ˆGSE305636ï¼‰ï¼›ç ”ç©¶<strong>Prostaglandin E2-EP2/EP4ä¿¡å·é€šè·¯</strong>è¯±å¯¼è‚¿ç˜¤ç›¸å…³Tregè¡¨å‹ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿ï¼ˆGSE282089ï¼‰ã€‚<br />
*   <strong>ç¥ç»ç§‘å­¦ä¸å‘è‚²</strong>ï¼šé‰´å®š<strong>21ä¸‰ä½“ç»¼åˆå¾ç›¸å…³CSF2RBçªå˜</strong>åœ¨<strong>äººç±»å°èƒ¶è´¨ç»†èƒ</strong>ä¸­èµ‹äºˆ<strong>é˜¿å°”èŒ¨æµ·é»˜ç—…æŠµæŠ—æ€§</strong>ï¼ˆscRNA-Seq, bulk RNA-Seqï¼ŒGSE252237, GSE252236ï¼‰ï¼›é˜æ˜<strong>è„‘è†œæºæ€§ç»´ç”²é…¸</strong>é€šè¿‡æŠ‘åˆ¶Notchå’ŒSox2è°ƒæ§<strong>ç¥ç»å‘ç”Ÿ</strong>ï¼ˆGSE282382ï¼‰ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
*   <strong>å¤šç»„å­¦æ•´åˆ</strong>ï¼šç»“åˆRNA-seqã€ATAC-seqã€ChIP-seqç­‰æŠ€æœ¯ï¼Œæ·±å…¥è§£æåŸºå› è°ƒæ§æœºåˆ¶ï¼Œå¦‚<strong>PDHBç¼ºå¤±å¯¹äººç±»èƒšèƒå¹²ç»†èƒåˆ†åŒ–çš„å½±å“</strong>ï¼ˆGSE285135, GSE285133, GSE285132ï¼‰ã€‚<br />
*   <strong>æ ¸åŸºè´¨åŠŸèƒ½ç ”ç©¶</strong>ï¼šé€šè¿‡Hi-Cå’ŒATAC-seqæ­ç¤º<strong>æ ¸åŸºè´¨åœ¨ç»´æŒæŸ“è‰²è´¨ç»“æ„å’ŒåŸºå› è¯±å¯¼ä¸­çš„ä½œç”¨</strong>ï¼ˆGSE310527, GSE310524ï¼‰ã€‚</p>
<h3>ğŸ”¬ æœŸåˆŠæ–‡ç« </h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
èƒƒè‚ é“é—´è´¨è‚¿ç˜¤ï¼ˆGISTï¼‰ä¸­ï¼Œç™Œç—‡ç›¸å…³æˆçº¤ç»´ç»†èƒé€šè¿‡ PGK1 ä»‹å¯¼çš„ä»£è°¢é‡ç¼–ç¨‹ï¼Œæ˜¯å¯¼è‡´ä¼Šé©¬æ›¿å°¼è€è¯æ€§çš„é‡è¦æœºåˆ¶ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ¢ç©¶è€—å°½ T ç»†èƒä¸Šè°ƒ TNFR2 è¡¨è¾¾ï¼Œå¹¶é™åˆ¶æŠ—è‚¿ç˜¤å…ç–«çš„æœºåˆ¶ã€‚<br />
- æ­ç¤º SERPINB3 ä»‹å¯¼çš„é“œç®¡èµ·ä½œç”¨è€è¯æ€§ï¼Œå¹¶æå‡ºé¶å‘ SERPINB3â€“MAPK è½´ç³»ä»¥å¢å¼ºå…ç–«ç–—æ³•ååº”ã€‚<br />
- åˆ©ç”¨å•ç»†èƒè°±ç³»è¿½è¸ªæŠ€æœ¯ï¼Œè§£ææ€¥æ€§éª¨é«“æ€§ç™½è¡€ç—…ï¼ˆAMLï¼‰ä¸­ FLT3 æŠ‘åˆ¶å‰‚çš„è€è¯ç‰¹å¾åŠè‡´æ•ç­–ç•¥ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- é‡‡ç”¨å•ç»†èƒ RNA æµ‹åºå’Œæ–°å‹å•ç»†èƒè°±ç³»è¿½è¸ªæ–¹æ³•ï¼ˆReSisTraceï¼‰è¿›è¡Œæ·±å…¥ç ”ç©¶ã€‚</p>
<h3>ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
Bioconductoråœ¨éæ´²æ‰©å±•ï¼ŒåŸƒå¡ä¿„æ¯”äºšé¦–æ¬¡ä¸¾åŠçº¿ä¸‹è¯¾ç¨‹ï¼Œæ ‡å¿—ç€è¯¥åœ°åŒºç”Ÿç‰©ä¿¡æ¯å­¦èƒ½åŠ›å»ºè®¾çš„é‡è¦ä¸€æ­¥ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- æ¨å¹¿å’Œåº”ç”¨Bioconductorå·¥å…·è¿›è¡ŒåŸºå› ç»„å­¦å’Œè½¬å½•ç»„å­¦æ•°æ®åˆ†æã€‚<br />
- æå‡éæ´²åœ°åŒºç ”ç©¶äººå‘˜åœ¨è®¡ç®—ç”Ÿç‰©å­¦é¢†åŸŸçš„æŠ€èƒ½ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- Bioconductoråœ¨éæ´²çš„é¦–æ¬¡çº¿ä¸‹å®æ“åŸ¹è®­ï¼Œç›´æ¥é¢å‘å½“åœ°ç ”ç©¶äººå‘˜ã€‚<br />
- æ¨åŠ¨æ ‡å‡†åŒ–ã€å¯å¤ç°çš„ç”Ÿç‰©ä¿¡æ¯å­¦åˆ†ææµç¨‹åœ¨éæ´²çš„ç ”ç©¶å®è·µä¸­è½åœ°ã€‚</p>
<h3>ğŸ§ª åšå®¢æ›´æ–°</h3>
<blockquote>
<p><strong>ä»Šæ—¥ç„¦ç‚¹</strong>ï¼š<br />
ç ”ç©¶æ­ç¤ºSox9è›‹ç™½å¯å¢å¼ºå¤§è„‘æ¸…é™¤é˜¿å°”èŒ¨æµ·é»˜ç—…ç›¸å…³æ¯’æ€§æ–‘å—çš„èƒ½åŠ›ï¼›HSLè›‹ç™½åœ¨è„‚è‚ªç»†èƒæ ¸å†…çš„æ–°åŠŸèƒ½çªç ´äº†è„‚è‚ªä»£è°¢çš„ä¼ ç»Ÿè®¤çŸ¥ã€‚</p>
</blockquote>
<p><strong>ä¸»è¦æ–¹å‘</strong>ï¼š<br />
- ç¥ç»ç§‘å­¦ï¼šé€šè¿‡è°ƒæ§Sox9è›‹ç™½ï¼Œå¢å¼ºæ˜Ÿå½¢èƒ¶è´¨ç»†èƒæ¸…é™¤é˜¿å°”èŒ¨æµ·é»˜ç—…æ·€ç²‰æ ·è›‹ç™½çš„èƒ½åŠ›ã€‚<br />
- ä»£è°¢å­¦ï¼šå‘ç°HSLè›‹ç™½åœ¨è„‚è‚ªç»†èƒæ ¸å†…çš„å…¨æ–°ä½œç”¨ï¼Œå½±å“è„‚è‚ªç»†èƒåŠŸèƒ½ã€‚</p>
<p><strong>æŠ€æœ¯äº®ç‚¹</strong>ï¼š<br />
- åŠ¨ç‰©æ¨¡å‹ç ”ç©¶ï¼ˆå°é¼ ï¼‰åœ¨é˜¿å°”èŒ¨æµ·é»˜ç—…å’Œè„‚è‚ªä»£è°¢é¢†åŸŸå–å¾—æ–°å‘ç°ã€‚</p>
            </div><h2>ğŸ“š åˆ†ç±»æµè§ˆ</h2>
<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“° å…¬ä¼—å· (43æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>7+å•åŸºå› ç”Ÿä¿¡ï¼Œ2026å¹´å•åŸºå› å¦‚ä½•å‘æ–‡ï¼Ÿå¤§é‡ç©ºé—´è½¬å½•ç»„åˆ†æå¿…ä¸å¯å°‘ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šä¸œæ™“ç”Ÿç‰©<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç©ºé—´è½¬å½•ç»„ã€åŸºå› ç»„ã€è½¬å½•ç»„ã€ç”Ÿä¿¡<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2OTU2MzM2NA==&amp;mid=2247493040&amp;idx=1&amp;sn=986d936368ab6a56c1c186cd7144be69" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>Nat Cancer | ç™½è¡€ç—…å…ç–«é€ƒé€¸æœºåˆ¶æ­ç¤ºï¼ŒæŠ—ä½“æ¢å¤Tç»†èƒæ”»å‡»èƒ½åŠ›</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šå›¾çµåŸºå› <br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šcancerã€å…ç–«ã€Tç»†èƒã€æŠ—ä½“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šå°½ç®¡å…ç–«ç–—æ³•å–å¾—é‡å¤§è¿›å±•ï¼Œç™½è¡€ç—…æ²»ç–—é¢†åŸŸä»è¿›å±•æœ‰é™ã€‚æ€¥æ€§é«“ç³»ç™½è¡€ç—…ï¼ˆAMLï¼‰å§‹ç»ˆèƒ½æŠµæŠ—å…ç–«æ²»ç–—ï¼Œè¿™åæ˜ å‡ºæˆ‘ä»¬å¯¹ç™½è¡€ç—…ç»†èƒå¦‚ä½•é€ƒé€¸å…ç–«ç³»ç»Ÿæ”»å‡»çš„è®¤è¯†ä»ä¸å…¨é¢ã€‚Lundå¤§å­¦çš„ç ”ç©¶äººå‘˜è¿‘æ—¥æ­ç©¿äº†å…¶ä¸­ä¸€ç§é€ƒé€¸ä¼ä¿©ï¼Œå¹¶æˆåŠŸæ‰¾åˆ°ç ´è§£ä¹‹é“ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&amp;mid=2247555183&amp;idx=2&amp;sn=95bc910e8236d67f9989738771b4c940" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>ä¸å­¦çœŸçš„è¡€äºï¼roplsåŒ…ï¼Œä¸‰è¡Œä»£ç è½»æ¾æå®šå¤šå˜é‡åˆ†æï¼Œå¿«é€ŸæŒæ¡ä»£è°¢ç»„å­¦æ•°æ®å¯è§†åŒ–ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šäº‘ç”Ÿä¿¡<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€ä»£è°¢ç»„ã€RåŒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg5MDk3Mzg4OA==&amp;mid=2247498516&amp;idx=1&amp;sn=72bd811a879556ddb0a9dc6b32b0b156" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> â­ <strong>8+å¹²æ¹¿ç»“åˆæ¨¡æ¿æ–‡ç« ï¼Œç»“åˆåˆ†å‹å’Œå»ºæ¨¡è¯†åˆ«è„‚è´¨ä»£è°¢å…³é”®åŸºå› ï¼Œè¿›å±•å¢æ®–ï¼Œå‡‹äº¡ï¼Œä»£è°¢å’Œå…ç–«å¾®ç¯å¢ƒçš„å®éªŒéªŒè¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€å…ç–«å¾®ç¯å¢ƒã€ä»£è°¢<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504035&amp;idx=5&amp;sn=20167ff25311841639fa6273fb109992" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> â­ <strong>æœ€æ–°14+å¹²æ¹¿ç»“åˆSCIï¼Œä½œè€…é‰´å®šå‡ºå¹²æ‰°ç´ è¯±å¯¼çš„è¡°è€ CD8T ç»†èƒå¹¶æ­ç¤ºå…¶å¯¹å…ç–«æ²»ç–—çš„å½±å“ã€‚è¡°è€è™½è€ï¼Œä½†æ˜¯çœŸçš„ç«ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€è¡°è€ã€Tç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504035&amp;idx=3&amp;sn=36a93e4bcc309fa557b02599025523e2" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> â­ <strong>10.6åˆ†éè‚¿ç˜¤å¹²æ¹¿ç»“åˆç”Ÿä¿¡ï¼Œé¶å‘ CD177 + ä¸­æ€§ç²’ç»†èƒå‡è½»ç¼ºè¡€å†çŒæ³¨æŸä¼¤ã€‚é€‚åˆåŠ¨ç‰©å»ºæ¨¡æµ‹åºæ€è·¯ï¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡å°è¯¾å ‚<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€æµ‹åºã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šç‚¹å‡»æŸ¥çœ‹è¯¦æƒ…<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504035&amp;idx=2&amp;sn=f4e138a8e405a7f574f6416b05afedb8" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> â­ <strong>å•ç»†èƒ+ç©ºé—´å¤šç»„å­¦æ­ç¤ºç™Œç—‡ç›¸å…³æˆçº¤ç»´ç»†èƒçš„ä¿å®ˆç©ºé—´äºšå‹ä¸ç»†èƒé‚»åŸŸ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šä½œå›¾ä¸«<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡ã€å•ç»†èƒã€ç©ºé—´ç»„å­¦<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šæœ€è¿‘æœ‰å°ä¼™ä¼´åæ˜ æ”¶ä¸åˆ°æ¨é€ï¼Œå› ä¸ºå…¬ä¼—å·æ”¹äº†æ¨é€ç®—æ³•ï¼Œç°åœ¨éœ€è¦åŠ æ˜Ÿæ ‡ï¼Œå¤šç‚¹èµã€ç‚¹åœ¨çœ‹ï¼Œæ‰èƒ½å‡†æ—¶æ”¶åˆ°æ¨é€å“¦ã€‚<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=Mzg2NTE1MzU4NQ==&amp;mid=2247523461&amp;idx=1&amp;sn=69c34bb08fb26d6a377c95f47ce73f63" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> â­ <strong>å•ç»†èƒ+ç©ºè½¬+ä»£è°¢ç»„ï¼Œå…¬å¼€æ•°æ®é›†æ‰¾å‡ºäº®ç‚¹å°±èƒ½å‘1åŒº12åˆ†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šä»£è°¢ã€ä»£è°¢ç»„ã€å•ç»†èƒ<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248747&amp;idx=8&amp;sn=eb42f61c1b928995e6aee27a5548d25b" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> â­ <strong>Cancer Cellé‡ç£…ï¼šè‚¿ç˜¤ç«Ÿè¢«è‡ªå·±äººèƒŒåˆºï¼çªå˜å¼•çˆ†å…ç–«æ²»ç–—</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡äºº<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€cancerã€å…ç–«<br />
- ğŸ“ <strong>æè¿°</strong>ï¼š10æœˆ16æ—¥ï¼ŒCancer Cellå‘è¡¨äº†å¾·å·å¤§å­¦MDå®‰å¾·æ£®ç™Œç—‡ä¸­å¿ƒPadmanee Sharmaæ•™æˆå›¢é˜Ÿçš„é‡<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248747&amp;idx=3&amp;sn=e297e202d66d235da183064dd1855f71" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> â­ <strong>Natureå…ç–«å­¦ç»¼è¿° |è¿™ç»å¯¹æ˜¯ç”Ÿä¿¡å®è—ã€‚Tç»†èƒæ–°çš„äºšç¾¤åç§°å±‚å‡ºä¸ç©·ï¼Œè¯¥å’‹æ³¨é‡Šï¼Œçœ‹çœ‹Tç»†èƒå‘½åä¸“å®¶æŒ‡å—å…±è¯†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šç”Ÿä¿¡é’±åŒå­¦<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šå…ç–«ã€Tç»†èƒã€ç”Ÿä¿¡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šTç»†èƒæ³¨é‡Šå›½é™…å…±è¯†æŒ‡å—ï¼Œç»å¯¹é‡ç‚¹<br />
- ğŸ”— <a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495702&amp;idx=1&amp;sn=bfdbb42f0c55fd1e8e6b66f7dbdb98bc" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 33 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-å…¬ä¼—å·">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§¬ æ•°æ®å‰æ²¿ (27æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå‰10æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>GSE310880 é¶å‘ MEK/ERK é€šè·¯æŠ‘åˆ¶ P-ç³–è›‹ç™½å¹¶é€†è½¬å¤šå‘æ€§éª¨é«“ç˜¤çš„å¡éä½ç±³è€è¯æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šresistanceã€pathway<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Lidia Laletina ; Anastasiia Cherkasova ; Ekaterina Scherbakova ; Pavel Iamshchikov ; Natalia Koroleva ; Anna Lushnikova ; Alexey Komissarov ; Nikolay Kalitin ; Natalia MoiseevaSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensCarfilzomib (CFZ) is a cornerstone in the treatment of relapsed multiple myeloma (MM). However, its efficacy is limited by resistance mediated by the overexpression of the ABC-transporter P-glycoprotein (P-gp).The signaling pathways driving emergence of P-gp in MM remain unclear. To investigate this, we generated CFZ-resistant AMO-1/CFZ cells with P-gp overexpression by long-term selection. RNA sequencing of control AMO-1 and AMO-1/CFZ, sorted into two subpopulations P-gp HIGH and P-gp LOW, implicated the Ras/MEK/ERK pathway as the most likely signaling cascade involved in P-gp upregulation. We therefore evaluated two clinically used MAPK pathway inhibitors, cobimetinib and ulixertinib, for their ability to re-sensitize AMO-1/CFZ cells to CFZ. Co-administration at non-toxic concentrations enhanced sensitivity 5-fold with cobimetinib and 17-fold with ulixertinib. Analysis of combined MTT assay results, rhodamine efflux experiments, molecular docking, and western blotting revealed distinct actions. Ulixertinib primarily functions as a potent direct P-gp inhibitor. Conversely, non-toxic concentrations of cobimetinib sensitizes cells by suppressing MAPK signaling, though it also exhibits P-gp inhibition at higher concentrations. Both inhibitors at the ICâ‚…â‚€ concentration reduced P-gp expression. In conclusion, combining CFZ with MAPK pathway inhibitors like cobimetinib or ulixertinib represents a promising strategy to overcome P-gp-mediated resistance in ĞœĞœ.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310880" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>GSE309876 åŸƒåŠä¼ŠèšŠå°RNAåŸºå› ç»„å­¦å‘ç°å¯è§¦å‘RNAå¹²æ‰°ååº”çš„æ„ŸæŸ“æ€§ç—…æ¯’[RNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seqã€genomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Shruti Gupta ; Rohit Sharma ; Adeline Williams ; Irma Sanchez-Vargas ; Noah Rose ; Chao Zhang ; Alexander Crosbie-Villaseca ; Margarita Kyza-Karavioti ; Zheng Zhu ; Gargi Dayama ; Andrea Gloria-Soria ; Doug Brackney ; Jessica Manning ; Sarah Wheeler ; Angela Caranci ; Trinidad Reyes ; Massamba Sylla ; Athanase Badolo ; Jewelna Akorli ; Ogechukwu Aribodor ; Diego Ayala ; Wei-Liang Liu ; Chung-Hong Chen ; Chalmers Vasquez ; Cassandra Acosta ; Alongkot Ponlawat ; Tereza Magalhaes ; Brendan Carter ; Dawn Wesson ; Darred Surin ; Meg Younger ; Andre Costa-da-Silva ; Matthew DeGennaro ; Alexander Bergman ; Louis Lambrechts ; Carolyn McBride ; Ken Olson ; Eric Calvo ; Nelson LauSeries Type : Expression profiling by high throughput sequencingOrganism : Aedes aegypti ; Aedes albopictusWe report a global survey of viral small RNAs (vsmRNAs) from &gt;200 Aedes aegypti samples to identify many mosquito viruses that actively infect this prominent arboviral vector. Ae. aegypti viruses in the Americas were abundant, with some displaying geographical boundaries. Viruses infecting Asian Ae. aegypti were similar to those in the Americas and revealed the first wild example of dengue vsmRNAs. African Ae. aegypti displayed vsmRNAs from viruses unique to these African strains. Academic lab colonies generally lacked viruses, yet two commercial strains were deeply infected by a tombus-like virus that is related to plant viruses. Comparing matched viral long RNAs to vsmRNAs revealed viral transcripts evading the mosquito RNA interference (RNAi) pathway. By infecting mosquito cells with Ae. aegypti homogenates, we generated stably infected cell lines which produced vsmRNAs that were comparable to native mosquito vsmRNA patterns. Lastly, we demonstrate that these stably infected mosquito cells producing vsmRNAs can exert gene silencing of reporters bearing viral sequence segments, providing a potential explanation for how Ae. aegypti can tolerate the persistence of viral infections. This vsmRNA genomics approach in Ae. aegypti can add to existing vector surveillance approaches by discovering new viruses that persist in mosquito populations.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309876" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> <strong>GSE310321 ä¸™é…®é…¸æ¿€é…¶è‚Œè‚‰å‹ (PKM)-2 é€šè¿‡åœ¨ç¨³æ€å’Œæ‰©å¢è¿‡ç¨‹ä¸­è°ƒèŠ‚ä¸™é…®é…¸æ°§åŒ–æ¥ä¿ƒè¿› CD4 T ç»†èƒå­˜æ´»</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šT cellã€kinase<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jeff J Subleski ; Erika M Palmieri ; Jessica F Walls ; Steven Hsu ; Ian A Bettencourt ; Timothy R Gower ; Scott K Durum ; Daniel W McVicarSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusGlycolysis is an essential metabolic pathway for rapidly expanding T cells, but role of Pyruvate Kinase Muscle (PKM) 1 and 2 in regulating this process is underappreciated. Here, using a pharmacological activator and targeted deletion of PKM2 in T cells we delineated distinct functions of PKM1 and 2 in regulating CD4 T cell survival during homeostasis and expansion. Expanding PKM2-deficient CD4 T cells increased PKM1 expression with associated mitochondrial ROS-mediated cell death. Examination of T cell compartments revealed PKM2-deficient CD4 T cells were unaltered in the thymus but were significantly reduced in peripheral tissues as mice aged. The failure of PKM1 to protect CD4 T cells in the absence of PKM2 resulted in protection from T cell mediated colitis as pathogenic cell numbers were significantly reduced resulting in less severe disease compared to control cells. This study shows PKM2 is critical for CD4 T cell survival during expansion and homeostasis.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310321" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>GSE305636 å•ç»†èƒå®šä½ä¸æ£€æŸ¥ç‚¹å…ç–«ç–—æ³•ååº”ç›¸å…³çš„å¯å˜å‰ªæ¥</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šregex:immuno(logy|therapy|suppression)ã€single-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Jieyi Xiong ; Chen Gu ; Diether LambrechtsSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensEvidence suggests that alternative RNA splicing (AS) plays a critical role in tumor biology and may contribute to the generation of tumor antigens. Here, we develop a method to detect AS in short-read single-cell 5â€™-RNA-sequencing data, allowing us to uniquely characterize the heterogeneity and dynamic changes in AS in individual cell types within the tumor microenvironment. We identify numerous splicing events specific to either cancer cells or stromal cell types, or for triple-negative versus estrogen receptor-positive breast cancers. By correlating these splice events with expression of splicing regulators in individual cells, we also identify their potential mediators. For instance, we identify and functionally validate the Epithelial Splicing Regulatory Protein-1 (ESRP1) to drive AS in breast cancers responding to immune checkpoint blockade (ICB). Prioritization of splicing events based on their likelihood to represent tumor antigens reveals that their aggregated load also correlates with high immune activity in multiple cancers, while also predicting expansion of T-cells in breast cancers receiving ICB and prolonging long-term survival of cancer patients treated with ICB. Collectively, our method provides a framework for analyzing AS in single-cell data and defines a key role for AS in the response to ICB.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305636" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>GSE252237 äººç±»å°èƒ¶è´¨ç»†èƒä¸­ä¸ 21 ä¸‰ä½“ç›¸å…³çš„çƒ­ç‚¹ CSF2RB çªå˜èµ‹äºˆå¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…çš„æŠµæŠ—åŠ› (scRNA-Seq)</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimerã€scRNA<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mengmeng Jin ; Ziyuan Ma ; Peng JiangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiens ; Mus musculusWhile challenging, identifying individuals displaying resilience to Alzheimerâ€™s disease (AD) and understanding the underlying mechanism holds great promise for the development of new therapeutic interventions to effectively treat AD. Recent studies indicate that somatic mutations in hematopoietic cells may lead to both the instigation and resilience to neurodegeneration. Down syndrome (DS), or trisomy 21, is the most significant genetic risk factor for AD. Interestingly, some DS individuals show resilience to AD neuropathology and do not exhibit dementia signs. Notably, DS individuals face a heightened risk of myeloid leukemia due to somatic mutations in hematopoietic cells. Microglia dysfunction is a central mechanism in AD etiology. Here we hypothesize that somatic mutations associated with DS myeloid leukemia may impart resilience to microglia against AD. Using CRISPR-Cas9 gene editing, we introduce a DS-linked hotspot CSF2RB A455D mutation into human pluripotent stem cell (hPSC) lines derived from both DS and healthy individuals. Employing hPSC-based in vitro microglia culture and in vivo human microglia chimeric mouse brain models, we show that in response to pathological tau, the CSF2RB A455D mutation suppresses type-1 interferon signaling in both DS and control human microglia, independent of trisomy 21 genetic background. This mutation also reduces neuroinflammation and enhances phagocytic and autophagy functions, ameliorating senescent and dystrophic changes in human microglia. Furthermore, the CSF2RB A455D mutation promotes the development of a microglia subcluster with tissue repair properties. Importantly, human microglia carrying CSF2RB A455D provide protection to neuronal function, such as neurogenesis and synaptic plasticity. When co-transplanted into the same mouse brains, human microglia with CSF2RB A455D mutation phagocytize, outcompete, and gradually replace human microglia carrying the wildtype CSF2RB gene following pathological tau treatment. Our findings suggest the potential use of hPSC-derived CSF2RB A455D microglia to develop effective microglial replacement therapy for AD and other age-related neurodegenerative diseases, even without the need of depleting endogenous senescent microglia prior to cell transplantation.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252237" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>GSE252236 äººç±»å°èƒ¶è´¨ç»†èƒä¸­ä¸ 21 ä¸‰ä½“ç»¼åˆå¾ç›¸å…³çš„çƒ­ç‚¹ CSF2RB çªå˜èµ‹äºˆå…¶å¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…çš„æŠµæŠ—åŠ›ï¼ˆæ‰¹é‡ RNA æµ‹åºï¼‰</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimerã€RNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Mengmeng Jin ; Ziyuan Ma ; Peng JiangSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensWhile challenging, identifying individuals displaying resilience to Alzheimerâ€™s disease (AD) and understanding the underlying mechanism holds great promise for the development of new therapeutic interventions to effectively treat AD. Recent studies indicate that somatic mutations in hematopoietic cells may lead to both the instigation and resilience to neurodegeneration. Down syndrome (DS), or trisomy 21, is the most significant genetic risk factor for AD. Interestingly, some DS individuals show resilience to AD neuropathology and do not exhibit dementia signs. Notably, DS individuals face a heightened risk of myeloid leukemia due to somatic mutations in hematopoietic cells. Microglia dysfunction is a central mechanism in AD etiology. Here we hypothesize that somatic mutations associated with DS myeloid leukemia may impart resilience to microglia against AD. Using CRISPR-Cas9 gene editing, we introduce a DS-linked hotspot CSF2RB A455D mutation into human pluripotent stem cell (hPSC) lines derived from both DS and healthy individuals. Employing hPSC-based in vitro microglia culture and in vivo human microglia chimeric mouse brain models, we show that in response to pathological tau, the CSF2RB A455D mutation suppresses type-1 interferon signaling in both DS and control human microglia, independent of trisomy 21 genetic background. This mutation also reduces neuroinflammation and enhances phagocytic and autophagy functions, ameliorating senescent and dystrophic changes in human microglia. Furthermore, the CSF2RB A455D mutation promotes the development of a microglia subcluster with tissue repair properties. Importantly, human microglia carrying CSF2RB A455D provide protection to neuronal function, such as neurogenesis and synaptic plasticity. When co-transplanted into the same mouse brains, human microglia with CSF2RB A455D mutation phagocytize, outcompete, and gradually replace human microglia carrying the wildtype CSF2RB gene following pathological tau treatment. Our findings suggest the potential use of hPSC-derived CSF2RB A455D microglia to develop effective microglial replacement therapy for AD and other age-related neurodegenerative diseases, even without the need of depleting endogenous senescent microglia prior to cell transplantation.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252236" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>GSE310970 èƒå„¿è„‘ç»„ç»‡ RNA æµ‹åºï¼ŒDSS å¤„ç†ç»„æˆ– DSS+ Gsdmd-cko ç»„</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šRNA-seq<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusThe maternal mice had two genotypes: wild-type (WT) and conditional knockout of intestinal epithelial Gsdmd (Gsdmd cko). Pregnant mice were treated with DSS starting on gestational day 9.5 (GD9.5) for 4 days, and immediately afterward, the cortex of fetuses at embryonic day 13.5 (E13.5) was dissected for RNA sequencing.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310970" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>GSE310969 å¦Šå¨ å°é¼ ç»“è‚ ä¸Šçš®ç»†èƒæµ‹åº</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsequencing<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributor : Huiyang JiaSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusRNA sequencing was performed on the colorectal epithelium of pregnant mice in the normal group and the colitis group. For the colitis group, pregnant mice were treated with 2.5% DSS for 4 days starting on embryonic day 9.5 (E9.5); subsequently, CD326+ CD45- cells were sorted by flow cytometry for RNA sequencing.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310969" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>GSE309873 åŸƒåŠä¼ŠèšŠå°RNAåŸºå› ç»„å­¦å‘ç°å¯è§¦å‘RNAå¹²æ‰°ååº”çš„æ„ŸæŸ“æ€§ç—…æ¯’[miRNA-seq]</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šgenomics<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Shruti Gupta ; Rohit Sharma ; Adeline Williams ; Irma Sanchez-Vargas ; Noah Rose ; Chao Zhang ; Alexander Crosbie-Villaseca ; Margarita Kyza-Karavioti ; Zheng Zhu ; Gargi Dayama ; Andrea Gloria-Soria ; Doug Brackney ; Jessica Manning ; Sarah Wheeler ; Angela Caranci ; Trinidad Reyes ; Massamba Sylla ; Athanase Badolo ; Jewelna Akorli ; Ogechukwu Aribodor ; Diego Ayala ; Wei-Liang Liu ; Chung-Hong Chen ; Chalmers Vasquez ; Cassandra Acosta ; Alongkot Ponlawat ; Tereza Magalhaes ; Brendan Carter ; Dawn Wesson ; Darred Surin ; Meg Younger ; Andre Costa-da-Silva ; Matthew DeGennaro ; Alexander Bergman ; Louis Lambrechts ; Carolyn McBride ; Ken Olson ; Eric Calvo ; Nelson LauSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Aedes aegypti ; Aedes albopictusWe report a global survey of viral small RNAs (vsmRNAs) from &gt;200 Aedes aegypti samples to identify many mosquito viruses that actively infect this prominent arboviral vector. Ae. aegypti viruses in the Americas were abundant, with some displaying geographical boundaries. Viruses infecting Asian Ae. aegypti were similar to those in the Americas and revealed the first wild example of dengue vsmRNAs. African Ae. aegypti displayed vsmRNAs from viruses unique to these African strains. Academic lab colonies generally lacked viruses, yet two commercial strains were deeply infected by a tombus-like virus that is related to plant viruses. Comparing matched viral long RNAs to vsmRNAs revealed viral transcripts evading the mosquito RNA interference (RNAi) pathway. By infecting mosquito cells with Ae. aegypti homogenates, we generated stably infected cell lines which produced vsmRNAs that were comparable to native mosquito vsmRNA patterns. Lastly, we demonstrate that these stably infected mosquito cells producing vsmRNAs can exert gene silencing of reporters bearing viral sequence segments, providing a potential explanation for how Ae. aegypti can tolerate the persistence of viral infections. This vsmRNA genomics approach in Ae. aegypti can add to existing vector surveillance approaches by discovering new viruses that persist in mosquito populations.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309873" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>GSE305595 å•ç»†èƒè½¬å½•ç»„å›¾è°±æ­ç¤ºå°é¼ ä¸‹é¢Œè½¯éª¨ä¸­éª¨éª¼ç¥–ç»†èƒçš„å±‚çº§ç»“æ„å’ŒåŒºåŸŸæ¨¡å¼</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šsingle-cell<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šContributors : Ikue Tosa ; Wakana Kitagawa ; Benjamin Kheyfets ; Ziyi Wang ; Hyerin Yoon ; Evan Stipano ; Mitsuaki Ono ; Mildred C EmbreeSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusSkeletal and synovial joint development involves distinct skeletal stem/progenitor populations. However, in neural crest-derived temporomandibular joint (TMJ), skeletal stem/progenitor lineage dynamics and ossification programs remain poorly defined. Here, we performed single-cell RNA sequencing (scRNA-seq) on mouse mandibular cartilage at embryonic day 16.5 (E16.5), postnatal day 0 (P0), and 13 weeks to construct a high-resolution atlas of skeletal stem/progenitor populations. The outer perichondrium lining the mandibular cartilage contained Lgr5âºPthlhâº cells expressing Dlx5, suggesting intramembranous ossification. In contrast, a previously uncharacterized Crabp1âº subpopulation within the inner perichondrium expressed Nrg1, Lsamp, Tac1, and Igfbp5, consistent with early cartilage progenitors biased toward endochondral ossification. These results reveal a spatial division of ossification modes with both intramembranous and endochondral growth and clarify the transcriptional regulation underlying TMJ development. Our findings provide a framework for understanding neural crestâ€“derived skeletal stem/progenitor cell regulation and may inform cartilage regenerative strategies.<br />
- ğŸ”— <a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE305595" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<blockquote>
<p>ğŸ’¡ è¯¥æ¥æºè¿˜æœ‰ 17 æ¡å†…å®¹ï¼Œè¯¦è§ <a href="#æ›´å¤š-æ•°æ®å‰æ²¿">æ–‡æœ«</a></p>
</blockquote>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ”¬ æœŸåˆŠæ–‡ç«  (10æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨10æ¡ï¼‰</h4>
<p><strong>1.</strong> â­ <strong>ç™Œç—‡ç›¸å…³æˆçº¤ç»´ç»†èƒé€šè¿‡ PGK1 ä»‹å¯¼çš„ä»£è°¢é‡ç¼–ç¨‹ä¿ƒè¿›èƒƒè‚ é“é—´è´¨è‚¿ç˜¤ä¸­çš„ä¼Šé©¬æ›¿å°¼è€è¯æ€§</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€ç™Œç—‡ã€ä»£è°¢ã€è€è¯ã€è‚ é“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: èƒƒè‚ é“é—´è´¨è‚¿ç˜¤ï¼ˆGISTï¼‰æ˜¯èƒƒè‚ é“æœ€å¸¸è§çš„è‚‰ç˜¤ï¼Œä¸»è¦ç”±æ¿€æ´»ä¸‹æ¸¸ä¿¡å·é€šè·¯ï¼ˆåŒ…æ‹¬ PI3K/AKT/mTORï¼‰çš„ c-KIT æˆ– PDGFRA çªå˜é©±åŠ¨ã€‚è™½ç„¶ä¼Šé©¬æ›¿å°¼ï¼ˆä¸€ç§ä¸€çº¿é…ªæ°¨é…¸æ¿€é…¶æŠ‘åˆ¶å‰‚ TKIï¼‰åˆæœŸæœ‰æ•ˆï¼Œä½† 20 ä¸ªæœˆå†…çº¦ 50%çš„æ‚£è€…å‡ºç°è€è¯æ€§ã€‚äºŒçº¿å’Œä¸‰çº¿ TKIsï¼Œå¦‚èˆ’å°¼æ›¿å°¼å’Œé›·æˆˆæ‹‰éå°¼ï¼Œç–—æ•ˆæœ‰é™ï¼Œå‡¸æ˜¾äº†è¿«åˆ‡éœ€è¦è§£å†³è€è¯æœºåˆ¶ã€‚æ­¤å‰çš„ç ”ç©¶ä¸»è¦èšç„¦äºè€è¯æ€§çš„é—ä¼ é©±åŠ¨å› ç´ ï¼Œå¿½è§†äº†è‚¿ç˜¤å¾®ç¯å¢ƒï¼ˆTMEï¼‰çš„ä½œç”¨ã€‚æœ¬ç ”ç©¶ä¸­ï¼Œæˆ‘ä»¬ç¡®å®šäº†ç™Œç—‡ç›¸å…³æˆçº¤ç»´ç»†èƒï¼ˆCAFsï¼‰åœ¨é©±åŠ¨ä¼Šé©¬æ›¿å°¼è€è¯æ€§ä¸­çš„ä½œç”¨ã€‚å…·ä½“æ¥è¯´ï¼ŒCAFs åˆ†æ³Œçš„ TGF-Î²1 å¢å¼ºäº† CCN2/Rack1 ä¿¡å·ã€‚CCN2/Rack1 è½´æ¿€æ´» PI3K/AKT ä¿¡å·ï¼Œè¯±å¯¼ PGK1 çš„ç£·é…¸åŒ–å’Œçº¿ç²’ä½“ç¿»è¯‘ï¼Œä¿ƒè¿›æ”¯æŒè‚¿ç˜¤å­˜æ´»å’Œè€è¯æ€§çš„ä»£è°¢é‡ç¼–ç¨‹ã€‚å…±åŸ¹å…»æ¨¡å‹å’Œå•ç»†èƒ RNA æµ‹åºæ­ç¤ºäº†ä¸åŒçš„ CAF äºšå‹ï¼Œå¹¶æ˜¾ç¤º CAF åˆ†æ³Œçš„ TGF-Î²1 å¢<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992342662341046272/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> â­ <strong>è€—å°½çš„ T ç»†èƒå¯¹ TNFR2 çš„ä¸Šè°ƒå…ˆäº TOX è¡¨è¾¾ï¼Œé™åˆ¶æŠ—è‚¿ç˜¤å’ŒæŠ—ç—…æ¯’å…ç–«</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€Tç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ç›®çš„ï¼šè€—å°½ä»£è¡¨ä¸€ç³»åˆ—ç¨‹åºåŒ–çš„ T ç»†èƒåˆ†åŒ–çŠ¶æ€ï¼Œä¹Ÿæ˜¯ T ç»†èƒåŠŸèƒ½éšœç¢çš„é‡è¦æ¨¡å¼ã€‚T ç»†èƒä»å‰ä½“ç»†èƒè¿›å±•åˆ°ç»ˆæœ«è€—å°½ä¸è½¬å½•å› å­ TOX çš„ä¸Šè°ƒæœ‰å…³ã€‚ç„¶è€Œï¼Œæˆ‘ä»¬å¯¹è°ƒæ§ TOX è¡¨è¾¾åŠä»å‰ä½“å‘ç»ˆæœ«è€—å°½è½¬å˜çš„å› ç´ çš„ç†è§£ä»ç„¶ä¸å®Œæ•´ã€‚å®éªŒè®¾è®¡ï¼šé‡‡ç”¨å•ç»†èƒ RNA æµ‹åºè¯„ä¼°è‚¿ç˜¤æµ¸æ¶¦å‹äººç±»å’Œå°é¼  CD8+ T ç»†èƒä¸­ TNF å—ä½“çš„è¡¨è¾¾æƒ…å†µã€‚åˆ©ç”¨æµå¼ç»†èƒæœ¯è¯„ä¼° CD8+ T ç»†èƒä¸Šçš„è€—å°½æ ‡å¿—ç‰©å’Œ TNF å—ä½“ã€‚é‡‡ç”¨ä½“å‹ RNA æµ‹åºæŠ€æœ¯è¯æ˜ TNFR2 åœ¨æ•´ä½“è€—å°½è°±ä¸­çš„ä½œç”¨ã€‚æœ€åï¼Œé€šè¿‡ TNFR2 KO å°é¼ å’Œæ‹®æŠ—å‰‚ï¼Œè¯å®äº† TNFR2 å¯¹æ•´ä½“æŠ—è‚¿ç˜¤ååº”çš„å½±å“ã€‚ç»“æœï¼šæˆ‘ä»¬å‘ç° TNFR2 çš„ä¸Šè°ƒä¸è¡¨å‹æ ‡å¿—ç‰©å’ŒåŠŸèƒ½å¢åŠ ä¸€è‡´ï¼Œåæ˜ ç»ˆæœ«ç–²åŠ³ã€‚TNFR2 çš„ä¸§å¤±å¸¦æ¥äº†ä¸€ç§è¡¨è¾¾ TIM3 ä½† TOX æ°´å¹³é™ä½ä¸”å…·å¤‡å‰ä½“ç»†èƒå’Œç»ˆæœ«è€—å°½ç»†èƒåŠŸèƒ½ç‰¹å¾çš„æ–°å‹ T ç»†èƒç¾¤ä½“ã€‚TIM3+ TNFR2 KO T ç»†èƒè¡¨ç°å‡ºå‡å°‘çš„è€—å°½è½¬å½•ç¨‹åºå’Œå¢å¼ºçš„<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992342654950682624/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>3.</strong> â­ <strong>é¶å‘ SERPINB3â€“MAPK è½´ç³»ä»‹å¯¼çš„é“œç®¡èµ·ä½œç”¨è€è¯æ€§å¢å¼ºæŠ—è‚¿ç˜¤å…ç–«ç–—æ³•çš„ååº”</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚¿ç˜¤ã€å…ç–«ã€è€è¯<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: é“œç®¡èŒèˆŒèŒç—‡æ˜¯ä¸€ç§æ–°å‘ç°çš„ç»†èƒæ­»äº¡å½¢å¼ï¼Œä¸é“œç¨³æ€å’Œè›‹ç™½è´¨è„‚è´¨åŒ–å¯†åˆ‡ç›¸å…³ã€‚é€šè¿‡å¤šç»„å­¦æ–¹æ³•ï¼Œæˆ‘ä»¬é¦–å…ˆæ­ç¤º SERPINB3 èµ‹äºˆèƒ°è…ºç™Œä¸­çš„åµå·¢èµ·ä½œç”¨çš„è€è¯æ€§ï¼Œå¹¶å…·æœ‰æ²»ç–—æ€§ç”Ÿç‰©æ ‡å¿—ç‰©çš„åŠŸèƒ½ã€‚æœºåˆ¶ä¸Šï¼ŒSERPINB3 é€šè¿‡æ¿€æ´» MAPK ä¿¡å·é€šè·¯æŠ‘åˆ¶ FDX1 è½¬å½•ï¼Œä»è€Œèµ‹äºˆä¿ƒåµé…¶æŠ—æ€§ã€‚æˆ‘ä»¬è¿›ä¸€æ­¥è¯æ˜ SERPINB3 ç›´æ¥ä¸ MEK1 ç›¸äº’ä½œç”¨ï¼Œé˜»ç¢å…¶ç”±ä¼´ä¾£è›‹ç™½ä»‹å¯¼çš„è‡ªå™¬é™è§£ï¼Œæœ€ç»ˆå¯¼è‡´ MAPK ä¿¡å·é€šè·¯çš„æŒç»­æ¿€æ´»ã€‚æ­¤å¤–ï¼Œæˆ‘ä»¬å‘ç° SERPINB3 é€šè¿‡ä¸Šè°ƒè‚¿ç˜¤ç»†èƒä¸Šçš„ PD-L1 è¡¨è¾¾ï¼Œä¿ƒè¿›èƒ°è…ºç™Œå…ç–«é€ƒé¿ã€‚è¿™ä¸€ç°è±¡ä¿ƒä½¿å¼€å‘äº†ä¸€ç§ä¸‰é‡ç»„åˆç­–ç•¥ï¼ŒåŒ…æ‹¬ MAPK æŠ‘åˆ¶ã€ä¿ƒæˆä¹³è…ºä¿ƒæˆå’ŒÎ±PD-1 æ²»ç–—ï¼Œç”¨äºé«˜ SERPINB3 è¡¨è¾¾çš„èƒ°è…ºç™Œæ‚£è€…ã€‚ä¸ºæ­¤ï¼Œæˆ‘ä»¬è¿›ä¸€æ­¥å¼€å‘äº†ä¸€ç§å¯Œå«é“œç¦»å­å’Œ MEK æŠ‘åˆ¶å‰‚çš„é‡‘å±æœ‰æœºæ¡†æ¶ï¼ˆMOFï¼‰ï¼Œæ˜¾è‘—è§¦å‘è‚¿ç˜¤ç‰¹å¼‚æ€§é“œç®¡åˆ†ç¦»å¹¶å¢å¼ºæŠ—è‚¿ç˜¤å…ç–«ã€‚æ€»ä¹‹ï¼ŒSERPINB3 ä½œä¸ºé¢„æµ‹æ€§<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992355252458860544/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>4.</strong> <strong>å•ç»†èƒè°±ç³»è¿½è¸ªæ­ç¤ºäº†æ€¥æ€§éª¨é«“æ€§ç™½è¡€ç—…ä¸­ FLT3 æŠ‘åˆ¶å‰‚çš„è€è¯ç‰¹å¾å’Œè‡´æ•ç­–ç•¥</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè€è¯ã€å•ç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: å°½ç®¡ FLT3 æŠ‘åˆ¶å‰‚æ˜¾è‘—æ”¹å–„äº†ä¾µè¢­æ€§ FLT3 çªå˜æ€¥æ€§é«“ç³»ç™½è¡€ç—…ï¼ˆAMLï¼‰çš„æ²»ç–—ï¼Œä½†è€è¯æ€§çš„å‡ºç°ä»æ˜¯ä¸€å¤§æŒ‘æˆ˜ã€‚åœ¨æœ¬ç ”ç©¶ä¸­ï¼Œæˆ‘ä»¬åº”ç”¨äº†æ–°å¼€å‘çš„å•ç»†èƒè°±ç³»è¿½è¸ªæ–¹æ³• ReSisTraceï¼Œè¯†åˆ«å‡ºåœ¨ AML ä¸­å¯¹ FLT3 æŠ‘åˆ¶å‰‚ midostaurin å’Œ quizartinib å…·æœ‰å†…æºæ€§è€è¯æˆ–æ•æ„Ÿä¸”å¸¦æœ‰ FLT3-ITD çªå˜çš„ç»†èƒã€‚å¯¹è¿™äº›ç»†èƒåŸºå› è¡¨è¾¾è°±çš„æ¯”è¾ƒæ­ç¤ºäº†è½¬å½•æŠµæŠ—ç‰¹å¾ï¼ŒåŒ…æ‹¬ GSPT1 çš„ä¸Šè°ƒã€‚åŸºå› CRISPR-Cas9-mediatedæ•²é™¤å¯¼è‡´æ€¥æ€§é«“è´¨ç™½ç»†èƒï¼ˆAMLï¼‰å¯¹å¥æ‰æ›¿å°¼æ²»ç–—çš„æ•æ„Ÿæ€§å¢åŠ ã€‚æ­¤å¤–ï¼Œç”¨å°åˆ†å­ CC-90009 é¶å‘ GSPT1ï¼Œç»“åˆ FLT3-ITD ç»†èƒç³»å’Œä¸»è¦ AML æ‚£è€…æ ·æœ¬æ—¶ï¼Œè¡¨ç°å‡ºå¼ºçƒˆçš„ååŒæ•ˆåº”ã€‚æ­¤å¤–ï¼Œåœ¨ FLT3-ITD é˜³æ€§ AML æ‚£è€…æ¥æºå¼‚ç§ç§»æ¤ï¼ˆPDXï¼‰å°é¼ æ¨¡å‹ä¸­ï¼ŒCC-90009 å’Œå–½æ‰æ›¿å°¼è”åˆä½¿ç”¨ç›¸æ¯”å•ç‹¬æ²»ç–—è¡¨ç°å‡ºæ˜¾è‘—æ›´é«˜çš„æŠ—è‚¿ç˜¤ç–—æ•ˆ<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992342644875964416/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>5.</strong> <strong>å‹˜è¯¯ï¼šPOLARIX ç ”ç©¶äº”å¹´ç»“å±€ï¼Œæ¯”è¾ƒ Pola-R-CHP å’Œ R-CHOP åœ¨å¼¥æ¼«æ€§å¤§ B ç»†èƒæ·‹å·´ç˜¤æ‚£è€…ä¸­çš„æ•ˆæœ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ·‹å·´ã€Bç»†èƒ<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992114627968872448/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>6.</strong> <strong>ä¸–å«ç»„ç»‡ä¸ºå„¿ç«¥å‹å¥½å‹ç™Œç—‡è¯ç‰©åˆ¶å®šæ–°çš„å…¨çƒæ ‡å‡†</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992140405070737408/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>7.</strong> <strong>ç ”ç©¶å°† 50 å²ä»¥ä¸‹å¥³æ€§çš„è¶…åŠ å·¥é£Ÿå“æ‘„å…¥ä¸è‚ é“æ¯è‚‰è”ç³»èµ·æ¥</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šè‚ é“<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext:<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992141560073007104/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>8.</strong> <strong>å¦‚æœè¿åŠ¨æ˜¯è¯ä¸¸ï¼Œæˆ‘ä»¬éƒ½ä¼šç»™ç™Œç—‡æ‚£è€…å¼€å®ƒã€‚ä½†äº‹å®å¹¶éå¦‚æ­¤</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šç™Œç—‡<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992331496432709632/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>9.</strong> <strong>ä¼˜åŒ–æ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸´åºŠè¯•éªŒä¸­çš„å¯¹ç…§ç»„ï¼šBRUIN-CLL-321 è¯•éªŒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ·‹å·´<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992331497372233728/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>10.</strong> <strong>å›å¤ï¼šä¼˜åŒ–æ…¢æ€§æ·‹å·´ç»†èƒç™½è¡€ç—…ä¸´åºŠè¯•éªŒä¸­çš„å¯¹ç…§ç»„ï¼šBRUIN-CLL-321 è¯•éªŒ</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šæ·‹å·´<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šSecret hovertext: ä¸´åºŠè‚¿ç˜¤å­¦æ‚å¿—ï¼Œå°åˆ·å‰ã€‚<br />
- ğŸ”— <a href="https://m.x-mol.com/paper/1992331498269814784/t" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ“Š å­¦ç‚¹ç”Ÿä¿¡ (1æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨1æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>éæ´²ç”Ÿç‰©å¯¼ä½“ï¼šåŸƒå¡ä¿„æ¯”äºšé¦–ä¸ªçº¿ä¸‹è¯¾ç¨‹</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šBioconductor<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šIntroduction Following the success of our first in-person Bioconductor course in Nairobi earlier this year, we continued building momentum across the continent with Ethiopiaâ€™s first Bioconductor workshop, held in Addis Ababa from 25â€“29 August 2... Continue reading: Bioconductor in Africa: Ethiopiaâ€™s First In-Person Course<br />
- ğŸ”— <a href="https://www.r-bloggers.com/2025/11/bioconductor-in-africa-ethiopias-first-in-person-course/" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<details>
<summary style="text-align: right; direction: rtl; padding: 10px 15px; background: linear-gradient(135deg, #f8f9fa 0%, #e9ecef 100%); border-right: 4px solid #667eea; font-weight: 600; cursor: pointer; margin: 15px 0; border-radius: 6px;">ğŸ§ª åšå®¢æ›´æ–° (2æ¡)</summary>
<div class="details-content">
<h4>è¯¦ç»†å†…å®¹ï¼ˆå…¨éƒ¨2æ¡ï¼‰</h4>
<p><strong>1.</strong> <strong>å¢åŠ æŸç§è›‹ç™½è´¨çš„æ‘„å…¥æœ‰åŠ©äºå¤§è„‘æŠµå¾¡é˜¿å°”èŒ¨æµ·é»˜ç—…ã€‚</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šAlzheimer<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers discovered that raising the protein Sox9 can help the brainâ€™s astrocytes clear out toxic plaque buildup linked to Alzheimerâ€™s. In mouse models that already showed memory problems, activating these cells improved cognitive performance. The treatment also reduced plaque levels over time. The work points toward a natural, cell-based way to slow Alzheimerâ€™s decline.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251123085550.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
<p><strong>2.</strong> <strong>æ–°çš„è‚¥èƒ–ç—‡å‘ç°æ”¹å†™äº†æ•°åå¹´æ¥å…³äºè„‚è‚ªä»£è°¢ç§‘å­¦çš„è®¤çŸ¥</strong><br />
- âœï¸ <strong>ä½œè€…</strong>ï¼šæœªçŸ¥ä½œè€…<br />
- ğŸ·ï¸ <strong>å…³é”®è¯</strong>ï¼šmetabolism<br />
- ğŸ“ <strong>æè¿°</strong>ï¼šResearchers have uncovered a surprising new role for the HSL protein: beyond breaking down fat, it also works inside the nucleus of fat cells to keep them functioning properly. When HSL is missing, fat tissue doesnâ€™t expand as expectedâ€” instead, it shrinks, leading to lipodystrophy. This unexpected discovery helps explain why both obesity and fat-loss disorders share similar health risks, and it opens up fresh paths for understanding metabolic diseases at a time when obesity affects billions worldwide.<br />
- ğŸ”— <a href="https://www.sciencedaily.com/releases/2025/11/251123115712.htm" target="_blank" rel="noopener noreferrer">æŸ¥çœ‹åŸæ–‡</a></p>
</div>
</details>

<h2>ğŸ“Š å…³é”®è¯ç»Ÿè®¡</h2>
<table class="keywords-table">
<thead>
<tr>
<th>å…³é”®è¯</th>
<th>å‡ºç°æ¬¡æ•°</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tç»†èƒ</td>
<td>10</td>
</tr>
<tr>
<td>å…ç–«</td>
<td>10</td>
</tr>
<tr>
<td>è‚¿ç˜¤</td>
<td>8</td>
</tr>
<tr>
<td>ä»£è°¢</td>
<td>7</td>
</tr>
<tr>
<td>ç”Ÿä¿¡</td>
<td>6</td>
</tr>
<tr>
<td>è€è¯</td>
<td>6</td>
</tr>
<tr>
<td>cancer</td>
<td>6</td>
</tr>
<tr>
<td>åŸºå› ç»„</td>
<td>5</td>
</tr>
<tr>
<td>å•ç»†èƒ</td>
<td>5</td>
</tr>
<tr>
<td>RNA-seq</td>
<td>5</td>
</tr>
<tr>
<td>Alzheimer</td>
<td>5</td>
</tr>
<tr>
<td>ç™Œç—‡</td>
<td>4</td>
</tr>
<tr>
<td>æ·‹å·´</td>
<td>4</td>
</tr>
<tr>
<td>ä»£è°¢ç»„</td>
<td>3</td>
</tr>
<tr>
<td>è¡°è€</td>
<td>3</td>
</tr>
<tr>
<td>ç¥ç»</td>
<td>3</td>
</tr>
<tr>
<td>pathway</td>
<td>3</td>
</tr>
<tr>
<td>è‚ é“</td>
<td>3</td>
</tr>
<tr>
<td>ATAC-seq</td>
<td>3</td>
</tr>
<tr>
<td>è½¨è¿¹</td>
<td>2</td>
</tr>
</tbody>
</table>
<hr />
<h2>ğŸ“ æ›´å¤šå†…å®¹</h2>
<details>
<summary><a name="æ›´å¤š-å…¬ä¼—å·"></a>ğŸ“° å…¬ä¼—å· å…¶ä»–å†…å®¹ (33æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg5NjgxNjkwOA==&amp;mid=2247503144&amp;idx=1&amp;sn=400d36a0c8cda70483c4abb226adb9cb" target="_blank" rel="noopener noreferrer">ä»£è°¢ | Nature | ä»£è°¢é€‚åº”å¼•å¯¼ç»„ç»‡å†ç”Ÿè¿‡ç¨‹ä¸­çš„ç»†èƒå‘½è¿</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI4MjY5ODI1Nw==&amp;mid=2247496770&amp;idx=1&amp;sn=462887bb84b7c318187234a33ab3942d" target="_blank" rel="noopener noreferrer">STMï¼šå¹²æ‰°ç´ ä¿¡å·è¯±å¯¼CD8+ Tç»†èƒè¡°è€ä¿ƒè¿›ä¸‰é˜´æ€§ä¹³è…ºç™Œæ²»ç–—è€è¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkyMTI1MTYxNA==&amp;mid=2247519939&amp;idx=1&amp;sn=e84f7cb78b33ea8553dfd2483bc3b4e4" target="_blank" rel="noopener noreferrer">æ–°å·¥å…· CellMentorï¼šåŸºäºç›‘ç£å¼ NMF çš„å•ç»†èƒæ•°æ®é™ç»´ä¸æ•´åˆåˆ©å™¨ï¼Œç²¾å‡†è¯†åˆ«ç¨€æœ‰ç»†èƒç¾¤</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504035&amp;idx=1&amp;sn=7d54bb94a3f00d4b7c38e94b5156e40e" target="_blank" rel="noopener noreferrer">æœ€æ–°11+ç”Ÿä¿¡ï¼Œèšç„¦åŸºè´¨ç»†èƒ-å…ç–«ç»†èƒçš„äº’ä½œç½‘ç»œã€‚æœ¬æ–‡å®éªŒå®Œç¾è¯å®ç”Ÿä¿¡ç»“æœï¼Œå¹²æ¹¿ç»“åˆæ°åˆ°å¥½å¤„ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkwMzY2NjkwNg==&amp;mid=2247495681&amp;idx=1&amp;sn=66636c9a729094b5a6a6638faa5d8bb2" target="_blank" rel="noopener noreferrer">NC |è¿™ä¸ªå€¼å¾—äº†è§£ä¸‹ï¼Œç©ºé—´ä»£è°¢é…åˆç©ºé—´è½¬å½•å’Œå•ç»†èƒåšçš„å°‘ï¼Œé æ•°æ®åˆ†æè¿˜èƒ½å†²ä¸€å†²</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI5MDQzNjY2OA==&amp;mid=2247569121&amp;idx=1&amp;sn=e9d0c92b6c54b741086242458aae4349" target="_blank" rel="noopener noreferrer">ã€Šç§‘å­¦ã€‹å­åˆŠï¼šä¸‰é‡ç–—æ³•å‡»é€€è‚¿ç˜¤â€œä¿é•–â€ï¼æˆ–æ‰“ç ´ä¹³è…ºç™Œè€è¯å›°å±€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247659068&amp;idx=1&amp;sn=2fc22e7fe3b8b1d85039d64d22e1d281" target="_blank" rel="noopener noreferrer">æµ™æ±Ÿå¤§å­¦é˜®ä¸€éªå›¢é˜ŸTrends in Geneticsç»¼è¿° | ä¸‰ç»´åŸºå› ç»„æµ‹åºæŠ€æœ¯çš„åäº”å¹´ï¼šå›é¡¾ã€ç°çŠ¶ä¸å±•æœ›</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU0ODQyNjQxOA==&amp;mid=2247555183&amp;idx=1&amp;sn=a1c161d35541622098f43adbe46752bb" target="_blank" rel="noopener noreferrer">Nature ï½œ è€¶é²å¤§å­¦æ¨Šè£é™¢å£«æ­ç¤ºè„‘å‘è‚²å’Œç¥ç»ç‚ç—‡çš„ç©ºé—´åŠ¨åŠ›å­¦</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxMDY1MjU1OA==&amp;mid=2247488575&amp;idx=1&amp;sn=9590361b6745a46854eba948ff43e40e" target="_blank" rel="noopener noreferrer">æ–‡çŒ®åˆ†äº«| Nature Biotechnology|ä½ çš„ä¸“å±ç§‘ç ”åŠ©ç†ï¼šCellWhispererâ€”â€”å¯èŠå¤©çš„ç»†èƒæ¢ç´¢å·¥å…·</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2MTExNTkwNA==&amp;mid=2247573687&amp;idx=1&amp;sn=c1cb4c5ccf0480931c532d42e3bc98c3" target="_blank" rel="noopener noreferrer">Cancer Cell+1ï¼ç™Œç»†èƒä¼‘çœ æ–°æœºåˆ¶ï¼Œç«Ÿæ˜¯ç»†èŒåœ¨ä½œç¥Ÿï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248747&amp;idx=5&amp;sn=b967fe6c4dc40b94066f0f476292bd79" target="_blank" rel="noopener noreferrer">é¡¶åˆŠé‡Œç¨‹ç¢‘çªç ´ï¼å“ˆä½›å›¢é˜Ÿç»˜ 170 ä¸‡ T ç»†èƒå›¾è°±ï¼Œç”Ÿä¿¡æ³¨é‡Šæœ‰äº† â€œé»„é‡‘æ ‡å°ºâ€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248747&amp;idx=1&amp;sn=f4e19727af075b589e8aefb509444278" target="_blank" rel="noopener noreferrer">CAR-Tæ— æ•ˆï¼Ÿå¿«çœ‹è¿™é‡Œï¼Nature Geneticsé”å®šæ·‹å·´ç˜¤çš„å…ç–«é»‘æ´</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU1OTkyMTE4Mg==&amp;mid=2247489010&amp;idx=1&amp;sn=c0c6f9d820890362ae75bd950e231873" target="_blank" rel="noopener noreferrer">Cancer Cell+1ï¼è‚¿ç˜¤ç»†èƒä¼‘çœ æ–°æœºåˆ¶ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510635&amp;idx=1&amp;sn=b772e8aca870540e4c2396fd3a8231dd" target="_blank" rel="noopener noreferrer">ç‚ç—‡æ€§è‚ ç—…æ²»ç–—æ–°ç­–ç•¥ï¼å¤æ—¦å¤§å­¦è¯å­¦é™¢æˆšå»ºå¹³å›¢é˜Ÿå¼€å‘æ–°å‹ä»¿ç”Ÿçº³ç±³é¢—ç²’ï¼Œç²¾å‡†é¶å‘è‚ é“ç›Šç”ŸèŒå¹¶è°ƒèŠ‚å…¶åŠŸèƒ½</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkxODY4NDEwMA==&amp;mid=2247490095&amp;idx=1&amp;sn=e2f13f52e16ebb0a22a3fc24754a8062" target="_blank" rel="noopener noreferrer">çº¿ç²’ä½“å—æŸä¼šå¼•å‘ç¥ç»ç³»ç»Ÿç–¾ç—…ï¼Ÿè¿™10 ç§è¥å…»ç‰©è´¨æˆ–è®¸èƒ½å¸®ä¸Šå¿™</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzI1Njk4ODE0MQ==&amp;mid=2247533976&amp;idx=1&amp;sn=cd14df79e1742e9f65950b7c699658f4" target="_blank" rel="noopener noreferrer">åŸºäºSignacçš„monocle3è½¨è¿¹åˆ†æå­¦ä¹ </a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkwMjYyMDA1OA==&amp;mid=2247489304&amp;idx=1&amp;sn=5ca10d57ec5a85f7d738a79e06ff2111" target="_blank" rel="noopener noreferrer">åŸºäºSignacçš„monocle3è½¨è¿¹åˆ†æå­¦ä¹ </a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzUzMTEwODk0Ng==&amp;mid=2247538225&amp;idx=1&amp;sn=a382206056abe470b810610270547584" target="_blank" rel="noopener noreferrer">ç©ºé—´èšç±»åˆ†æä¹‹cellcharter</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzYyNDMwNjg3Nw==&amp;mid=2247484094&amp;idx=1&amp;sn=98a79e1bd51780da93619a7d97a06a7b" target="_blank" rel="noopener noreferrer">å¿…æ‡‚ï¼šå¿ƒè„è¡€æ¶²å¾ªç¯</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg3NDE3NTk4MA==&amp;mid=2247504035&amp;idx=4&amp;sn=580ba7d3202c5ffd3a24f87ee29fa0ba" target="_blank" rel="noopener noreferrer">æ°¨åŸºé…¸ä»£è°¢æ˜¯çœŸçš„ç«ï¼Œå¹²æ¹¿ç»“åˆè½»æ¾å‘7.5åˆ†2åŒºæ–‡ç« ã€‚ç°åœ¨ä¸‹æ‰‹è¿˜ä¸æ™šï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247659068&amp;idx=3&amp;sn=4f41066d886829bf5133d100af003334" target="_blank" rel="noopener noreferrer">é—«é“å¹¿/é’Ÿæ–‡å½¬/ææ˜å·ç­‰Trends in Cell Biologyç»¼è¿° | ç—…æ¯’ç›¸å…³æ¶æ€§è‚¿ç˜¤ä¸­çš„ç£·é…¸è‚Œé†‡åŠ¨æ€è°ƒæ§</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5MDcwNzg0MA==&amp;mid=2247659068&amp;idx=2&amp;sn=925c6539370126645a995c52edd6196b" target="_blank" rel="noopener noreferrer">å¼ äºŒèƒå›¢é˜ŸTrends in Neurosciencesç»¼è¿°ä¸¨è°ƒæ§å“ºä¹³åŠ¨ç‰©æ˜¼å¤œèŠ‚å¾‹çš„åˆ†å­å’Œç¥ç»æœºåˆ¶çš„ç ”ç©¶è¿›å±•</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzAxMDkxODM1Ng==&amp;mid=2247547169&amp;idx=1&amp;sn=b789ac481f4ecc79691d095837a8fb2e" target="_blank" rel="noopener noreferrer">2025å¹´10æœˆ_ç”Ÿä¿¡å…¥é—¨_é©¬æ‹‰æ¾ç­”ç–‘ç¬”è®°</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507612&amp;idx=3&amp;sn=54ae1fc7a37f9855df46fe40d421eb01" target="_blank" rel="noopener noreferrer">Nature | å‘Šåˆ«ç»“æ„å…ˆéªŒï¼šEvoæ¨¡å‹å¦‚ä½•åˆ©ç”¨â€œåŸºå› ç»„è¯­ä¹‰â€å®ç°åŠŸèƒ½åŸºå› çš„ä»å¤´è®¾è®¡ï¼Ÿ</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzkzODIxMDY5NQ==&amp;mid=2247507612&amp;idx=2&amp;sn=e036f662671ef7a69758a65b9c0abe8f" target="_blank" rel="noopener noreferrer">T ç»†èƒ â€œèº«ä»½è®¤è¯â€ å¤§æ›´æ–°ï¼å…¨çƒç§‘å­¦å®¶ç»Ÿä¸€å‘½åè§„åˆ™ï¼Œå†ä¹Ÿä¸ææ··äº†</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2MTExNTkwNA==&amp;mid=2247573688&amp;idx=1&amp;sn=ef05059c65fcadcc740b5d081b819391" target="_blank" rel="noopener noreferrer">èšç„¦è¡°è€ï¼Œåˆ˜å…‰æ…§å›¢é˜Ÿ2025è¿è·çªç ´ï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248747&amp;idx=7&amp;sn=c958e44ed4cdc73260426075947ef169" target="_blank" rel="noopener noreferrer">Natureï¼šscWGS+scRNAè§£å¯†å…¨åŸºå› ç»„å€å¢çš„æ¼”åŒ–åŠ¨æ€</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248747&amp;idx=4&amp;sn=bb83c9f0b88065b1e57ee2a4edd5ce18" target="_blank" rel="noopener noreferrer">åˆ«å‚»äº†ï¼å¤šç»„å­¦åªåšå…³è”å’Œé€šè·¯ï¼Ÿè¿™æ³¢è¡€äºï¼</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzA5NjU5NjQ4MA==&amp;mid=2651248747&amp;idx=2&amp;sn=4d88730c6aada0ec89ddbd38abe6b425" target="_blank" rel="noopener noreferrer">è…¾è®¯ç™»26.6åˆ†Natureå­åˆŠï¼Œåªæœ‰ä½ æƒ³ä¸åˆ°çš„è›‹ç™½è´¨ï¼æ²¡æœ‰è¿™ä¸ªæ¨¡å‹é¢„æµ‹ä¸äº†çš„</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU3OTYwNjk1NA==&amp;mid=2247523471&amp;idx=1&amp;sn=7a6a32aa565659b5c896dfa9c060f25c" target="_blank" rel="noopener noreferrer">å¤§ç‰›è®¿è°ˆå½•-Craig Venterç•…è°ˆäººç±»åŸºå› ç»„è®¡åˆ’å¾—ä¸å¤±</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MjM5MzQ4NTk4MA==&amp;mid=2656510635&amp;idx=3&amp;sn=038dcc1e5508a97f867f544e8fb2e424" target="_blank" rel="noopener noreferrer">ç²¾ç¡®é¶å‘ï¼ä¸­å›½åŒ»ç§‘å¤§å­¦é™„å±ç¬¬ä¸€åŒ»é™¢ï¼šå¢å¼ºèƒƒç™Œå…ç–«æ²»ç–—æœ‰å‰æ™¯çš„ç­–ç•¥</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=Mzg2MDY1NTYyOQ==&amp;mid=2247499125&amp;idx=1&amp;sn=a2a3b4b39b65e0221659cadfa740d2fa" target="_blank" rel="noopener noreferrer">åŸºç¡€æ›´æ–°--visium HDçš„åŸºç¡€è´¨æ§æ±‡æ€»</a></li>
<li><a href="https://mp.weixin.qq.com/s?__biz=MzU5OTgxNzU3NQ==&amp;mid=2247558438&amp;idx=1&amp;sn=43243eaea4bc064dd2173a19d9406554" target="_blank" rel="noopener noreferrer">ä»Šæ™šä¸ƒç‚¹ | é¶å‘CD24ç ´è§£è‚ºç™ŒEGFR-TKIè€è¯å›°å±€</a></li>
</ul>
</div>
</details>

<details>
<summary><a name="æ›´å¤š-æ•°æ®å‰æ²¿"></a>ğŸ§¬ æ•°æ®å‰æ²¿ å…¶ä»–å†…å®¹ (17æ¡)</summary>
<div class="details-content">
<ul>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE264013" target="_blank" rel="noopener noreferrer">GSE264013 å°é¼ ç»“è‚ ç™Œç»†èƒç³» CMT-93 ä¸­ Piezo1 ä¾èµ–æ€§åŸºå› è¡¨è¾¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310869" target="_blank" rel="noopener noreferrer">GSE310869 ç ”ç©¶è¡¨æ˜ï¼Œè¥¿è¾¾ç±³é…®å’Œå®‰ç½—æ›¿å°¼é€šè¿‡æŠ‘åˆ¶Hippoä¿¡å·é€šè·¯åœ¨Jurkatç»†èƒä¸­å‘æŒ¥ååŒä½œç”¨ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310838" target="_blank" rel="noopener noreferrer">GSE310838 å¼‚è´¨æ€§è€è¯ç™Œç»†èƒå…·æœ‰ç‹¬ç‰¹ä¸”å¯åˆ©ç”¨çš„è¯ç‰©æ•æ„Ÿæ€§ç‰¹å¾</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310679" target="_blank" rel="noopener noreferrer">GSE310679 æ™šæœŸç»†èƒè´¨ç›‘è§†é€šè·¯ç¡®ä¿æ ¸ç³–ä½“å®Œæ•´æ€§</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310601" target="_blank" rel="noopener noreferrer">GSE310601 æˆçº¤ç»´ç»†èƒç»„è›‹ç™½å»ä¹™é…°åŒ–é…¶-1 ä¿ƒè¿›ç¼ºè¡€å†çŒæ³¨æŸä¼¤åçš„è‚¾é—´è´¨çº¤ç»´åŒ–ã€‚</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310574" target="_blank" rel="noopener noreferrer">GSE310574ï¼šç”¨SspAå’ŒHDMå¤„ç†çš„å°é¼ çš®è‚¤ä¸­åˆ†ç¦»çš„Tç»†èƒçš„scRNAæµ‹åº</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310527" target="_blank" rel="noopener noreferrer">GSE310527 æ ¸åŸºè´¨é€šè¿‡ç»´æŒæŸ“è‰²è´¨æ–‘ç‚¹å…³è”å’ŒåŒºå®¤åŒ–æ¥è°ƒèŠ‚åŸºå› è¯±å¯¼ [Hi-C]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310524" target="_blank" rel="noopener noreferrer">GSE310524 æ ¸åŸºè´¨é€šè¿‡ç»´æŒæŸ“è‰²è´¨æ–‘ç‚¹å…³è”å’ŒåŒºå®¤åŒ–æ¥è°ƒæ§åŸºå› è¯±å¯¼ [ATAC-Seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE310386" target="_blank" rel="noopener noreferrer">GSE310386 å£è…”ç»†èŒå¤±è°ƒé€šè¿‡åˆ†å­æ¨¡æ‹Ÿé©±åŠ¨è‡ªèº«å…ç–«æ€§å¿ƒè„ç—…</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE309419" target="_blank" rel="noopener noreferrer">GSE309419 å¯¹è¿‡è¡¨è¾¾æ–°å‹çŸ­ XIST è½¬å½•æœ¬å¼‚æ„ä½“çš„äººç±»ç»†èƒè¿›è¡Œ RNA-seq åˆ†æ</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285135" target="_blank" rel="noopener noreferrer">GSE285135 äººç±»èƒšèƒå¹²ç»†èƒåœ¨DEåˆ†åŒ–è¿‡ç¨‹ä¸­PDHBéƒ¨åˆ†ç¼ºå¤±çš„åŸºå› è¡¨è¾¾å’ŒæŸ“è‰²è´¨å¯åŠæ€§[RNA-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285133" target="_blank" rel="noopener noreferrer">GSE285133 äººç±»èƒšèƒå¹²ç»†èƒåœ¨DEåˆ†åŒ–è¿‡ç¨‹ä¸­PDHBéƒ¨åˆ†ç¼ºå¤±çš„åŸºå› è¡¨è¾¾å’ŒæŸ“è‰²è´¨å¯åŠæ€§[ChIP-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE285132" target="_blank" rel="noopener noreferrer">GSE285132 äººç±»èƒšèƒå¹²ç»†èƒåœ¨ DE åˆ†åŒ–è¿‡ç¨‹ä¸­ PDHB éƒ¨åˆ†ç¼ºå¤±çš„åŸºå› è¡¨è¾¾å’ŒæŸ“è‰²è´¨å¯åŠæ€§ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282382" target="_blank" rel="noopener noreferrer">GSE282382 è„‘è†œæ¥æºçš„è§†é»„é…¸é€šè¿‡æŠ‘åˆ¶ Notch å’Œ Sox2 æ¥è°ƒèŠ‚ç¥ç»å‘ç”Ÿ [ATAC-seq]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE282089" target="_blank" rel="noopener noreferrer">GSE282089 å‰åˆ—è…ºç´ E2-EP2/EP4ä¿¡å·é€šè·¯è¯±å¯¼è‚¿ç˜¤æµ¸æ¶¦æ€§Tregè¡¨å‹ä¿ƒè¿›è‚¿ç˜¤ç”Ÿé•¿</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE280913" target="_blank" rel="noopener noreferrer">GSE280913 äººç±»å°èƒ¶è´¨ç»†èƒä¸­ä¸ 21 ä¸‰ä½“ç›¸å…³çš„çƒ­ç‚¹ CSF2RB çªå˜èµ‹äºˆå¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…çš„æŠµæŠ—åŠ› [WGS]</a></li>
<li><a href="http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE252238" target="_blank" rel="noopener noreferrer">GSE252238 äººç±»å°èƒ¶è´¨ç»†èƒä¸­ä¸21ä¸‰ä½“ç»¼åˆå¾ç›¸å…³çš„çƒ­ç‚¹CSF2RBçªå˜èµ‹äºˆå…¶å¯¹é˜¿å°”èŒ¨æµ·é»˜ç—…çš„æŠµæŠ—åŠ›</a></li>
</ul>
</div>
</details>

<hr />
<p><em>ğŸ“… æŠ¥å‘Šç”Ÿæˆæ—¶é—´ï¼š2025-11-24 21:36</em><br />
<em>ğŸ¤– ç”± GitHub Actions è‡ªåŠ¨ç”Ÿæˆ</em></p>
    </div>
</body>
</html>